Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7486009
Reference Type
Journal Article
Title
Initial experience with the new ethylene vinyl alcohol copolymer based liquid embolic agent Menox in the endovascular treatment of cerebral arteriovenous malformations
Author(s)
Sirakov, S; Sirakov, A; Minkin, K; Penkov, M; Ninov, K; Hristov, H; Karakostov, V; Raychev, R
Year
2019
Is Peer Reviewed?
1
Journal
Journal of NeuroInterventional Surgery
ISSN:
1759-8478
EISSN:
1759-8486
Volume
11
Issue
10
Page Numbers
1040-1044
Language
English
PMID
31147436
DOI
10.1136/neurintsurg-2019-014963
Web of Science Id
WOS:000487552100018
URL
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85066464484&doi=10.1136%2fneurintsurg-2019-014963&partnerID=40&md5=d3d8cbbcb0bd35863e95a9599c9e9ac7
Exit
Abstract
BACKGROUND AND PURPOSE:
Liquid embolic agents (LEAs) are the determinant tool for successful embolization of cranial arteriovenous shunts. There are few currently available LEAs. The aim of the study was to summarize our initial experience with a recently introduced non-adhesive ethylene vinyl alcohol (EVOH) copolymer based LEA (Menox 18) in the endovascular treatment of cerebral arteriovenous malformations.
METHODS:
From April 2018 to November 2018, 24 patients harboring cerebral arteriovenous malformations underwent endovascular embolization with Menox 18. Clinical features, angiographic results, procedural details, complications, and follow-up details were prospectively collected and retrospectively analyzed.
RESULTS:
Curative embolization in one endovascular session was achieved in 14/24 (58.3%) of the treated patients. Partial embolization was achieved in 10 patients (42.6%) in whom staged treatment with radiosurgery or microsurgical resection was planned. No mortality was recorded in our series. Clinical complications after embolization occurred in 1/24 (4.66%) patients. No technical complications were noted CONCLUSIONS: Our pilot study suggests that the Menox embolization system offers similar technical and clinical results in comparison with the other currently available LEAs. Further studies with larger cohorts and long term follow-up data are needed to fully evaluate its efficacy.
Tags
IRIS
•
Arsenic Hazard ID
Lit Search Updates Jan 2019 to April 2021 (OPP)
New to this search
PubMed
Lit Search Updates Jan 2019 to August 2022
PubMed
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity